Condition:   Major Depressive Disorder
Interventions:   Drug: desvenlafaxine succinate sustained-release 50 mg/day;   Drug: desvenlafaxine succinate sustained-release 100 mg/day;   Drug: placebo
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Condition:   Major Depressive Disorder
Interventions:   Drug: desvenlafaxine succinate sustained release;   Drug: fluoxetine;   Drug: placebo
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Condition:   Major Depressive Disorder
Intervention:   Drug: DVS SR
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Condition:   Cancer
Interventions:   Drug: prasterone;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Breast Cancer;   Depression;   Fatigue;   Sleep Disorders
Interventions:   Drug: metformin hydrochloride;   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: enzyme-linked immunosorbent assay;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: quality-of-life assessment
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified February 2012